Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CAD | P27708 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7096450 | 0.80 | FOLH1 (0.32) | ALDH1A1 | |
| SCHEMBL22023061 | 0.78 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL9001169 | 0.76 | — | — | |
| Acrylamide SCHEMBL20571033 | 0.76 | TSHR (0.50) | ALDH1A1 | |
| SCHEMBL10899226 | 0.75 | — | — | |
| SCHEMBL28926887 | 0.73 | TSHR (0.40) | NPC1ALDH1A1CAD | |
| SCHEMBL1278056 | 0.73 | TSHR (0.58) | ALDH1A1 | |
| SCHEMBL28427630 | 0.71 | TSHR (0.46) | NPC1ALDH1A1CAD | |
| SCHEMBL1228638 | 0.71 | NPC1 (0.40) | NPC1ALDH1A1CAD | |
| SCHEMBL27662 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014064-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF SKIN | TOPIX PHARMACEUTICALS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12440432-B2 | Methods and compositions for treatment of skin | TOPIX PHARMACEUTICALS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4552650-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF SKIN | Topix Pharmaceuticals, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| EP-3713583-B1 | METHODS AND COMPOSITIONS FOR TREATMENT OF SKIN | TOPIX PHARMACEUTICALS INC (US) | 2025-01-22 | — | — | EP | disclosed |
| US-20240108556-A1 | SCAR TREATMENT COMPOSITION | TOPIX PHARMACEUTICALS, INC. | 2024-04-04 | — | — | US | disclosed |
| US-20240075112-A1 | SCAR TREATMENT COMPOSITION | TOPIX PHARMACEUTICALS, INC. | 2024-03-07 | — | — | US | disclosed |
| EP-4251196-A1 | SCAR TREATMENT COMPOSITION | Topix Pharmaceuticals, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-4251141-A1 | SCAR TREATMENT COMPOSITION | Topix Pharmaceuticals, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-116782923-A | Scar treatment composition | 塔普克斯制药公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116710081-A | Scar treatment composition | 塔普克斯制药公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20230173410-A1 | RESTORING ACCUMULATED DGA WITH RECLAIMER SPARGE LINE | SAUDI ARABIAN OIL COMPANY (SA) | 2023-06-08 | — | — | US | disclosed |
| WO-2022115859-A1 | SCAR TREATMENT COMPOSITION | TOPIX PHARMACEUTICALS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115858-A1 | SCAR TREATMENT COMPOSITION | TOPIX PHARMACEUTICALS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| EP-3713583-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF SKIN | Topix Pharmaceuticals, Inc. (US) | 2020-09-30 | — | — | EP | disclosed |
| CN-111372595-A | Methods and compositions for treating skin | 塔普克斯制药公司 | 2020-07-03 | — | — | CN | disclosed |
| WO-2019104222-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF SKIN | TOPIX PHARMACEUTICALS, INC. (US) | 2019-05-31 | — | — | WO | disclosed |
| US-20190151214-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF SKIN | TOPIX PHARMACEUTICALS INC (US) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108556-A1 | SCAR TREATMENT COMPOSITION | MMP1, MMP8, PLAT | NPC1 2304/4885ALDH1A1 296/4885CAD 996/4885 |
| US-20240075112-A1 | SCAR TREATMENT COMPOSITION | MMP1, MMP8, MMP2 | NPC1 2426/4885ALDH1A1 173/4885CAD 597/4885 |
| US-20260014064-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF SKIN | CUTA, HAO2, SLC14A1 | NPC1 851/4885ALDH1A1 291/4885CAD 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.